BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tzanakakis GN, Giatagana EM, Berdiaki A, Spyridaki I, Hida K, Neagu M, Tsatsakis AM, Nikitovic D. The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis. Cancers (Basel) 2021;13:2478. [PMID: 34069554 DOI: 10.3390/cancers13102478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Moreno Tellez C, Leyfman Y, D'Angelo SP, Wilky BA, Dufresne A. Immunotherapy in Sarcoma: Where Do Things Stand? Surg Oncol Clin N Am 2022;31:381-97. [PMID: 35715140 DOI: 10.1016/j.soc.2022.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Shao R, Wang Y, Li L, Dong Y, Zhao J, Liang W. Bone tumors effective therapy through functionalized hydrogels: current developments and future expectations. Drug Deliv 2022;29:1631-47. [PMID: 35612368 DOI: 10.1080/10717544.2022.2075983] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol 2022;15:34. [PMID: 35331296 DOI: 10.1186/s13045-022-01252-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
4 Giatagana E, Berdiaki A, Gaardløs M, Samsonov SA, Tzanakakis GN, Nikitovic D. Biglycan Interacts with Type I Insulin-like Receptor (IGF-IR) Signaling Pathway to Regulate Osteosarcoma Cell Growth and Response to Chemotherapy. Cancers 2022;14:1196. [DOI: 10.3390/cancers14051196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Piperigkou Z, Karamanos NK. Matrix Effectors and Cancer. Cancers (Basel) 2021;14:200. [PMID: 35008364 DOI: 10.3390/cancers14010200] [Reference Citation Analysis]
6 Catellani C, Ravegnini G, Sartori C, Angelini S, Street ME. GH and IGF System: The Regulatory Role of miRNAs and lncRNAs in Cancer. Front Endocrinol (Lausanne) 2021;12:701246. [PMID: 34484116 DOI: 10.3389/fendo.2021.701246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Giatagana EM, Berdiaki A, Tsatsakis A, Tzanakakis GN, Nikitovic D. Lumican in Carcinogenesis-Revisited. Biomolecules 2021;11:1319. [PMID: 34572532 DOI: 10.3390/biom11091319] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
8 Bădilă AE, Rădulescu DM, Niculescu AG, Grumezescu AM, Rădulescu M, Rădulescu AR. Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review. Cancers (Basel) 2021;13:4229. [PMID: 34439383 DOI: 10.3390/cancers13164229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chong ZX, Yeap SK, Ho WY. Unraveling the roles of miRNAs in regulating epithelial-to-mesenchymal transition (EMT) in osteosarcoma. Pharmacol Res 2021;172:105818. [PMID: 34400316 DOI: 10.1016/j.phrs.2021.105818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]